Veracyte Inc. reported third quarter 2025 total revenue of $131.9 million, up 14.0% from $115.9 million in the same period of 2024. Testing revenue rose 17.0% to $127.8 million, driven by growth in Decipher Prostate and Afirma tests. Product revenue increased 4.0% to $3.3 million. Biopharmaceutical and other revenue declined to $0.8 million from $3.1 million, attributed to the restructuring and liquidation proceedings of Veracyte SAS. Total gross margin for the quarter was 69.0%, compared to 68.0% a year earlier. Non-GAAP gross margin was 73.0%, up from 71.0%. The company highlighted continued momentum and upcoming launches of TrueMRD and Prosigna LDT as key business developments during the period.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251104771700) on November 04, 2025, and is solely responsible for the information contained therein.